To simplify the titration of infectious varicella-zoster virus (VZV), we generated a reporter cell line that produced luciferase in a dose-dependent manner upon infection with cell-free VZV. A few VZV-infected cells were detectable by coculturing with the cell line. We demonstrated the usefulness of the cell line for antiviral studies.
To simplify the titration of infectious varicella-zoster virus (VZV), we generated a reporter cell line that produced luciferase in a dose-dependent manner upon infection with cell-free VZV. A few VZV-infected cells were detectable by coculturing with the cell line. We demonstrated the usefulness of the cell line for antiviral studies.
Varicella-zoster virus (VZV) causes varicella on primary infection and zoster upon reactivation. Both conditions may be associated with severe complications (1) . For the treatment of VZVassociated diseases, acyclovir (ACV), valaciclovir, and famciclovir have been used widely (1, 25) . The number of approved drugs for treating VZV diseases is limited, and all of them have the same mode of action. The development of resistant strains and the ineffectiveness of available antivirals at preventing complications have necessitated a search for alternative compounds (7, 8, 25, 33) . Several new compounds have been under investigation (13, 20, 21, 31, 32) . Plaque reduction assays have been routinely used to screen and evaluate candidate compounds, but this method is made laborious and time consuming due to the slow growth of VZV in tissue culture. Some methods aimed at reducing the inconvenience have been developed (26, 27, 34) , as has a biochemical assay for characterization of ACV-resistant strains (29) . However, the unavailability of a rapid, high-throughput assay for titrating VZV has hampered efforts both to screen new compounds and to detect drug-resistant strains in a timely fashion.
Previously, we established a reporter cell line for human herpesvirus 8 and demonstrated its practical uses (10, 11, 14) . We report here the generation of a similar cell line for VZV by use of the following approach: (i) selection of the most suitable promoter from various promoters, (ii) identification of the minimum sequence length for efficient activation of the selected promoter to avoid nonspecific activation, (iii) establishment of a cell line that contains the reporter gene under the control of the minimum promoter, and (iv) characterization of the clone that performed best.
Characterization of individual VZV promoters and global VZV gene expression have been reported previously (4, 5, 12) .
On the basis of those studies, various DNA fragments containing known or putative VZV promoters (Table 1) were amplified from the nucleocapsid DNA of VZV pOka strain by PCR, cloned into a luciferase vector pGL3-Basic, and then analyzed for their responses to VZV infection in transient transfection experiments using BSC40 cells (3) and MeWo cells (9) . Among the promoters examined, the ORF9 promoter was most strongly activated in both cell lines (Fig. 1) . Activation of each promoter was also analyzed by cotransfection with a plasmid expressing VZV IE62. The correlation between infection-and IE62-mediated activation (Fig. 1C) was good, indicating that infection-mediated activation was VZV specific.
The minimal essential region for the ORF9 promoter was mapped to a 93-bp-long sequence by progressively truncating the promoter (Fig. 2) . The patterns of relative promoter activity among the constructs were similar in infected and IE62-transfected cells. A 2-bp substitution introduced into the upstream stimulating factor (USF) motif reduced the promoter activity, supporting the importance of the USF-binding site reported for some VZV promoters (16, 17, 19) . Since the presence of intact USF sites did not always correlate with promoter activity, further study will be needed to identify the sequence or context that makes the ORF9 promoter more responsive than the others.
Duplication of the minimal promoter region between 34 and as an internal control, by using FuGENE 6 (Roche). pGL3-Basic, a vector plasmid used to clone the promoters, was used as a negative control (Ϫ). At 24 h after transfection, the cells were infected with VZV at an multiplicity of infection of ϳ0.02, and 1 day later, both firefly and Renilla luciferase activities were determined by a chemiluminescent assay reaction (Dual-Glo luciferase assay system; Promega) followed by measurement of relative light units (RLU) with a luminometer (JNR AB2300; ATTO, Japan). 127 bp upstream of ORF9 (T9G) increased the promoter activity twofold. As such, our VZV reporter cell line was generated by transfecting MeWo cells with pGL-T9G, together with a plasmid encoding the G418-resistant gene. The cell clone MV9G was selected from 86 G418-resistant clones based on two criteria: high luciferase activities on VZV infection and low background activity in the absence of the infection. The luciferase activity in MV9G increased gradually after infection, and the activity increased in a dose-dependent manner with a detection limit of 50 PFU (Fig. 3) . Coculturing of VZV-infected cells with MV9G cells induced luciferase activities with a detection limit of fewer than 10 infected cells (Fig.  3C) . No luciferase activity was detected in MV9G cells cocultured with cells infected with human cytomegalovirus (Towne), human herpesvirus 6 (Z29) (15) , or human herpesvirus 7 (SB) (2) or in MV9G cells directly infected with cell-free human cytomegalovirus. In contrast, MV9G cells infected with herpes simplex virus type 1 (HSV-1) resulted in luciferase activities similar to those seen with VZV-infected cells at 24 h after infection. However, at 48 h after infection, the infected cells showed strong cytopathic effect and their luciferase activities decreased, making it practical to distinguish HSV-1 infection from VZV infection.
For proof of concept, we evaluated the usefulness of MV9G cells for antiviral studies. MeWo cells were infected with cellassociated VZV or with cell-free VZV, cultured in the presence of ACV, and then cocultured with MV9G cells (Fig. 4A) . The 50% effective concentration (EC 50 ) of ACV against infec- (22, 23, 28) , and cultured in the presence of ACV for 2 days. Then, MV9G cells were overlaid and cocultured for 1 day. The luciferase activities in the ACV-treated cultures were expressed as percent RLU, with the activities obtained in the culture without inhibitor treatment used as a standard. Means and SDs of luciferase activities from triplicate wells are shown. (C) MeWo cells (7 ϫ 10 4 cells/well) were infected with cell-associated VZV, cultured for 2 days, and then cocultured with MV9G for 1 day (•, "coculture"). MV9G cells (7 ϫ 10 4 cells/well) were directly infected with 400 PFU of cell-free VZV, and cultured for 2 days (E, "direct infection"). Roscovitine was added at the indicated concentrations throughout the processes. Means and SDs of luciferase activities from triplicate wells are shown. tion with cell-free virus was Ͻ5 g/ml, which is consistent with the reported EC 50 (ϳ2 g/ml) (13, 18, 28) . The EC 50 against infection with cell-associated virus was 10 to 20 g/ml. Note that the EC 50 of ACV is known to be higher when infections are induced using cell-associated virus (24) . ACV treatment decreased luciferase activity only slightly in MV9G cells infected directly with cell-free virus; this was not unexpected, since the reporter gene expression in MV9G depends on a promoter that is active during the early phase of infection. We also examined the ability to detect ACV-resistant strains by coculturing MV9G cells with a small number of the cells that were infected and treated with ACV (Fig. 4B) . The average EC 50 of ACV for thymidine kinase (TK)-deficient strains was ϳ40 g/ml, which was much higher than that observed for TK-positive strains. The use of a reporter cell assay thus eliminates the need for laborious preparation of cell-free VZV stocks for the detection of ACV-resistant strains, providing a strong practical advantage.
Roscovitine, a kinase inhibitor, decreased luciferase activities, both in directly infected MV9G cells and in MV9G cells cocultured with MeWo cells that were infected in the presence of roscovitine (Fig. 4C ). This suggests that at least part of its inhibitory effect occurs in the early phase of infection, which is consistent with previous reports (30) . Cellular factors required for virus infection are attractive targets for the development of novel antiviral drugs. High-throughput screening of compounds in a cell-based assay is essential for that purpose, and MV9G appears to be ideally suited for that role.
In conclusion, the VZV reporter cell assays developed here are expected to foster the efficient evaluation of new antiviral compounds for the treatment of VZV-associated diseases.
